Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers
Section snippets
Detection
Bladder cancer may be diagnosed incidentally or because of symptoms. The main symptom of bladder cancer is hematuria, but in some patients, irritative symptoms are present from the very beginning. Incidental cancer is usually found on ultrasound performed for hematuria or irritative symptoms or for screening of symptoms unrelated to the urinary tract.
The clinical diagnosis of bladder cancer is usually made by flexible or rigid cystoscopy.4 Techniques of rigid and flexible cystoscopy are
Bladder tumor markers: why do we need them?
A noninvasive and accurate bladder tumor marker may be useful for bladder cancer screening and monitoring recurrence.
Ideal tumor marker
The attributes of an ideal tumor marker include technical ease of assaying, low intra-assay and interassay variability, and a high level of accuracy.2, 30
Good clinical practice in marker development
As in the setting of clinical trials research, there is a need to standardize different phases of tumor marker development and to develop general guidelines and protocols for broadly accepted (or at least broadly understood) principles of conducting and reporting translational marker studies.48, 49, 50, 51, 52 A number of leading scientists from a wide range of disciplines have chosen to focus on bladder cancer and the development of biomarkers to improve the diagnosis, prevention, and
Urine cytology: the standard noninvasive bladder tumor marker
Pathologic assessment of a randomly voided urine specimen is the standard noninvasive method in current use. Often called simply urine cytology, this approach is used primarily to monitor patients with a history of bladder cancer for the detection of new urothelial tumors. These new bladder neoplasms are traditionally called recurrences, but they are usually not at the same site as the index lesion and may not be the same grade or stage as the initial lesion. The pathologic interpretation of
Bladder tumor markers for diagnosis and monitoring recurrence
In this section, we will discuss various bladder cancer markers and tests that are commercially available or have shown potential to be clinically useful. Table I lists all of these tests and markers. The tumor markers are divided into 2 categories, soluble urine markers and cell-associated markers, based on whether urine specimens or exfoliated cells in urine are used in the assay.
Comparative analysis of bladder tumor markers (2000 to 2004)
Several studies have compared the sensitivity and specificity of a variety of markers with each other and with cytology. Most of the markers have a significantly higher sensitivity than cytology to detect bladder cancer. The sensitivity of many markers also varies with tumor grade, stage, and size. Some markers can detect bladder cancer recurrence before it can be detected by cystoscopy. Depending on the population, some markers show a specificity that is comparable to cytology in side-by-side
Standard Care for Bladder Cancer Detection and Surveillance
Cystoscopy and pathologic examination of biopsy specimens is the standard of care for the detection of bladder cancer. Periodic cystoscopies are the standard of care for surveillance. Surveillance schedules vary according to the risk factors of the disease.
Bladder Tumor Markers: Why Do We Need Them?
Screening of high-risk patients, but not the general population, using bladder tumor markers can offer early detection advantage and save medical costs. More studies are needed to identify accurate markers for bladder cancer screening.
Conclusion
Heterogeneity of bladder tumors to invade and metastasize and their frequent recurrence pose a challenge for physicians who treat patients with bladder cancer and for researchers who work on bladder cancer diagnosis, recurrence, and treatment-related areas. For most new bladder cancer cases, investigation begins when patients are symptomatic (eg, with hematuria or irritative voiding). This mode of detection is often inadequate for nearly 15% to 30% of these new cases with high-grade bladder
Acknowledgment
We acknowledge the editorial assistance of Cynthia Soloway and Dr. Adrienne Carmack for critically reviewing the manuscript.
References (212)
- et al.
Current bladder tumor tests does their projected utility fulfill clinical necessity?
J Urol
(2001) - et al.
Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladdera decision analytical approach
J Urol
(2002) - et al.
The natural history of bladder cancerimplications for therapy
Urol Clin North Am
(2000) Natural history of superficial bladder cancerprognostic features and long-term disease course
Urol Clin North Am
(1992)- et al.
Home screening for hematuriaresults of a multiclinic study
J Urol
(1992) - et al.
Hematuria home screeningrepeat testing results
J Urol
(1995) - et al.
A community study of bladder cancer screening by the detection of occult urinary bleeding
J Urol
(1992) - et al.
Sensitivity and specificity of commonly available bladder tumor markers versus cytology results of a comprehensive literature review and meta-analyses
Urology
(2003) - et al.
Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer
J Urol
(2002) - et al.
DD23 Biomarkera prospective clinical assessment in routine urinary cytology specimens from patients being monitored for TCC
Urol Oncol
(2002)
Comparison of molecular and conventional strategies for followup of superficial bladder cancer using decision analysis
J Urol
Sensitivity and specificity of commonly available bladder tumor markers versus cytology results of a comprehensive literature review and meta-analyses
Urology
Newly diagnosed bladder cancerthe relationship of initial symptoms, degree of microhematuria and tumor marker status
J Urol
A side-by-side comparison of cytology and biomarkers for bladder cancer detection
J Urol
The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer
Urol Oncol
Detection of upper urinary tract transitional cell carcinoma with ImmunoCyta preliminary report
Urology
Immunocyt and the HA-HAase urine tests for the detection of bladder cancera side by side comparison
Eur Urol
Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence
Urology
Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology
J Urol
Prognostic factorsguidelines for investigation design and state of the art analytical methods
Surg Oncol
Immunostaining of cytokeratin 20 in cells from voided urine for detection of bladder cancer
J Urol
The bladder tumor antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms
J Urol
Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA-A 21-1 and NMP 22 for evaluating symptomatic patients at risk for bladder cancer
J Urol
Tumor markers in the diagnosis of primary bladder cancera systemic review
J Urol
Diagnostic accuracy of urinary cytology and deoxyribonucleic acid flow cytometry and cytology on bladder washings during followup for bladder tumors
J Urol
Immunocyt test improves the diagnostic accuracy of urinary cytologyresults of a French multicenter study
J Urol
Urine based markers of urological malignancy
J Urol
Monitoring patients for bladder neoplasmswhat can be expected of urinary cytology consultations in daily practice?
Urology
Monitoring patients for bladder neoplasmswhat can be expected of urinary cytology consultations in clinical practice
Urol
Asymptomatic microscopic hematuriais investigation necessary?
J Clin Epidemiol
Neural network using combined urine nuclear matrix protein-22, monocyte chemoattractant protein-1 and urinary intercellular adhesion molecule-1 to detect bladder cancer
J Urol
A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine
J Urol
Comparison of screening methods in the detection of bladder cancer
J Urol
Value of urinary erythrocyte morphology in assessment of symptomless microhaematuria
Lancet
The application of human complement factor H-related protein (BTA TRAK) in monitoring patients with bladder cancer
Urol Clin North Am
Usefulness of the BTA STAT Test for the diagnosis of bladder cancer
Urology
The BTA stat testa tumor marker for the detection of upper tract transitional cell carcinoma
Urology
Human complement factor H related protein test for monitoring bladder cancer
J Urol
Sensitivity of human complement factor H related protein (BTA stat) test and voided urine cytology in the diagnosis of bladder cancer
J Urol
Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence
J Urol
Bladder tumor antigen assay as compared to voided urine cytology in the diagnosis of bladder cancer
Clin Chim Acta
Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma
J Urol
A user’s guide to flexible cystoscopy
Br J Urol
Diagnostic work-up
Longitudinal study of patients with bladder cancerfactors associated with disease recurrence and progression
The health economics of bladder cancera comprehensive review of public literature
Pharmacoeconomics
Urinary tract cancers found by homescreening with hematuria dipsticks in healthy men over 50 years of age
Cancer
Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations
Urology
Hematuria screening for bladder cancer
J Occup Med
Cited by (368)
Clinical Validation of the Proenkephalin (PENK) Methylation Urine Test for Monitoring Recurrence of Non–muscle-invasive Bladder Cancer
2024, European Urology Open ScienceBTA stat®, NMP22® BladderChek®, UBC® Rapid Test, and CancerCheck® UBC® rapid VISUAL as urinary marker for bladder cancer: Final results of a German multicenter study
2023, Urologic Oncology: Seminars and Original InvestigationsOff the fog to find the optimal choice: Research advances in biomarkers for early diagnosis and recurrence monitoring of bladder cancer
2023, Biochimica et Biophysica Acta - Reviews on Cancer
This work was supported by Grant No. R01 CA-72821-06A2 from the National Cancer Institute/National Institutes of Health (VBL)